Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Osteosarcoma and Soft Tissue Sarcomas
NCT03163381Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in osteosarcoma (OS) and soft tissue sarcoma (STS), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival at 6 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03163381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163381.